Merck & Co's Frazier: International Business Is Only Scratching The Surface
Merck & Co’s sales and EPS grow by double digits in the first quarter, with the performance of Keytruda, and growth in non-US markets, a feature of the three months.
You may also be interested in...
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.